SERNOVA WKN: A0LBCR ISIN: CA81732W1041 Kürzel: SVA Forum: Aktien Thema: Hauptdiskussion

Hier sitzt ein Admin der positive Infos zu SVA löscht, das Forum hier kann man in die Tonne treten.

https://ceo.ca/@thenewswire/jonathan-rigby-appointed-as-executive-chairman-for

Wer löscht denn hier offizielle Veröffentlichungen?? ?

Hi Nick, we are just as frustrated with the share price as investors are. Addressing your email below, cash plus cash equivalents at the end of Q2/24 was $8.5m so more than you are citing in your email below however you are correct the company will need additional cash. Management and the Board are working diligently to put a plan together as soon as there is something that can be shared publicly we will do so. With respect to news flow we did give investors a clinical update 2 weeks ago with another patient now insulin independent and will continue to bring updates as they become available. With respect to potential partnerships, Modi is working with several outside pharma companies on potential collaborations etc., however this is also highly confidential and cannot be disclosed until a transaction is consummated or we risk losing whatever work has been done. Depending on who the partner is and how the agreement is structured there could very well be cash as part of a transaction. The next pending regulatory approval would be for the thyroid program which we would like to get into the clinic early in 2025, you should expect that the associated filings are being worked on and we expect to have the IND filed by end of year. I hope this helps, Christopher Barnes Vice President Investor Relations Sernova

Meine Mail an Sernova: Dear Mr. Barnes, I have some further questions about the ongoing operational development of Sernova. The cash balance has decreased from $6,509,561 in Q1 2024 to $3,437,794 in Q2 2024. By the end of the month, based on my assumptions, I expect the cash balance to be significantly below $500,000. What specific measures have been taken so far to secure new capital? According to my projections, approximately $12 million per year is consumed, thus any capital measure should be substantial. The management does not seem interested in stabilizing the stock price—there is no news flow, no plan. Shareholders are facing a 70% loss within a year. A capital increase by issuing new shares would likely push the price per share below 10 cents, if not below 5 cents. There is currently no milestone operation in sight. Providing more information and perhaps an outlook on how the capital will be raised would at least strengthen the confidence of existing shareholders. Additionally, could you clarify the following points: Are there any strategic partnerships or collaborations in discussion to bolster financial stability? What is the current status of any pending regulatory approvals that might impact the company's financial standing? Thank you for your efforts.

Meine Mail an Sernova: Dear Mr. Barnes, I have some further questions about the ongoing operational development of Sernova. The cash balance has decreased from $6,509,561 in Q1 2024 to $3,437,794 in Q2 2024. By the end of the month, based on my assumptions, I expect the cash balance to be significantly below $500,000. What specific measures have been taken so far to secure new capital? According to my projections, approximately $12 million per year is consumed, thus any capital measure should be substantial. The management does not seem interested in stabilizing the stock price—there is no news flow, no plan. Shareholders are facing a 70% loss within a year. A capital increase by issuing new shares would likely push the price per share below 10 cents, if not below 5 cents. There is currently no milestone operation in sight. Providing more information and perhaps an outlook on how the capital will be raised would at least strengthen the confidence of existing shareholders. Additionally, could you clarify the following points: Are there any strategic partnerships or collaborations in discussion to bolster financial stability? What is the current status of any pending regulatory approvals that might impact the company's financial standing? Thank you for your efforts.